Skip to content
Everest Organics logo

Everest Organics

524790 BSE
₹239.90

Close ·

P/E
44.34
View as Markdown
MCP
Close 4 Nov 2026 ₹239.90 −157.60 −39.6% 1Y
Start ₹397.50

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
12.00%
Debt to Equity
0.66
EPS (TTM)
₹5.41
Book Value
₹79.69
Market Cap
—
P/E (TTM)
44.34
P/B
3.01
ROE
7.63%
Dividend Yield
0.21%
EBITDA
₹21.10 Cr
52W High
₹536.40
52W Low
₹197.00

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

44 Weak

Data confidence 100/100

Category scores

Quality
62
Good
Returns, margins, earnings quality 22% weight
Valuation
35
Poor
Cheap vs sector & own history 24% weight
Growth
44
Weak
Sales & profit trajectory 9% weight
Financial Health
25
Poor
Solvency, leverage, coverage 9% weight
Momentum
32
Poor
Trend strength, vol-adjusted 12% weight
Ownership
56
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

5
  • Stock is trading at 3.04 times its book value
  • The company has delivered a poor sales growth of 1.56% over past five years.
  • Company has a low return on equity of 2.49% over last 3 years.
  • Company has high debtors of 216 days.
  • Promoter holding has decreased over last 3 years: -14.6%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallNeutral676
OscillatorsBullish072
Moving AveragesStrong Bearish604

Key readings

RSI (14)
49.52
Neutral
MACD (12,26,9)
−1.95
Bullish
SMA (50)
249.57
Bearish
SMA (200)
289.34
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+7.07%
5Y+1.49%
3Y+2.31%
1Y+23.27%
TTM+5.49%

Net profit

Net profit growth by window
10YZero base
5Y−15.59%
3YZero base
1YTurned to profit
TTM−15.16%

Operating cash flow

Operating cash flow growth by window
10Y−5.44%
5Y−22.16%
3Y−39.43%
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+4.14 pp
5Y−2.44 pp
3Y+9.65 pp
1Y+5.80 pp
TTM+1.85 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹107 Cr
Mar 2018₹112 Cr
Mar 2019₹156 Cr
Mar 2020₹167 Cr
Mar 2021₹182 Cr
Mar 2022₹200 Cr
Mar 2023₹183 Cr
Mar 2024₹197 Cr
Mar 2025₹159 Cr
Mar 2026₹196 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1.00 Cr
Mar 2018₹2.00 Cr
Mar 2019₹8.00 Cr
Mar 2020₹11.00 Cr
Mar 2021₹14.00 Cr
Mar 2022₹1.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025−₹1.00 Cr
Mar 2026₹6.00 Cr

Quarterly Results

₹ Cr
524790 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
42.67
49.45
52.51
52.62
32.45
44.05
42.05
40.93
53.81
51
42.59
48.75
48.43
Expenses
40.15
46.74
49.71
49.67
36.11
40.62
38.03
37.49
49.37
45.87
39.05
42.05
44.1
Operating Profit
2.52
2.71
2.8
2.95
−3.66
3.43
4.02
3.44
4.44
5.13
3.54
6.7
4.33
OPM %
5.91%
5.48%
5.33%
5.61%
−11.28%
7.79%
9.56%
8.4%
8.25%
10.06%
8.31%
13.74%
8.94%
Other Income
0.22
0.24
0.13
0.3
0.33
0.14
0
0.22
0.55
0.29
0.25
0.16
0.42
Interest
1.29
1.49
1.45
1.24
1.29
1.35
1.4
1.15
1.31
1.23
1.23
2.76
1.63
Depreciation
1.29
1.32
1.33
1.85
1.47
1.47
1.47
1.56
1.52
1.52
1.52
1.93
1.59
PBT
0.16
0.14
0.15
0.16
−6.09
0.75
1.15
0.95
2.16
2.67
1.04
2.17
1.53
Tax %
75%
78.57%
93.33%
62.5%
0%
1.33%
0.87%
−206.32%
35.19%
56.93%
65.38%
−21.2%
26.8%
Net Profit
0.04
0.03
0.02
0.06
−6.09
0.74
1.14
2.91
1.41
1.16
0.36
2.63
1.11
EPS (₹)
0.05
0.04
0.02
0.08
−7.61
0.92
1.42
3
1.45
1.19
0.37
2.71
1.14

Profit & Loss

₹ Cr
524790 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
106
99
107
112
156
167
182
200
183
197
159
196
191
Expenses
98
94
101
105
138
148
159
194
182
186
152
176
171
Operating Profit
8
6
6
7
18
19
23
6
1
11
7
20
20
OPM %
7%
6%
6%
6%
11%
11%
13%
3.2%
0.5%
6%
4.5%
10%
10%
Other Income
0
0
1
1
1
1
1
2
7
1
1
1
1
Interest
3
3
3
3
3
3
3
3
3
5
5
7
7
Depreciation
3
3
2
3
3
3
3
4
4
6
6
6
7
PBT
2
0
2
2
12
14
17
2
0
1
−3
8
7
Tax %
20%
18%
24%
28%
39%
23%
21%
34%
311%
77%
−60%
31%
—
Net Profit
2
0
1
2
8
11
14
1
0
0
−1
6
5
EPS (₹)
—
0.54
1.69
2.14
9.39
13.62
17.15
1.42
−0.22
0.18
−1.33
5.72
5.41
Div. Payout %
0%
0%
0%
0%
11%
7%
9%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
524790 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
3
8
8
8
8
8
8
8
8
10
10
Reserves
−3
3
8
11
18
26
39
39
38
38
60
66
Borrowings
24
28
19
22
21
18
23
39
51
58
48
50
Other Liabilities
37
42
51
54
60
68
66
92
105
123
106
114
Total Liabilities
67
76
86
94
107
120
135
178
202
227
223
240
Fixed Assets
24
27
33
34
38
39
44
49
54
52
50
46
CWIP
0
1
1
1
0
1
0
8
12
21
23
22
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
42
47
52
60
68
80
92
121
136
153
150
171
Total Assets
67
76
86
94
107
120
135
178
202
227
223
240

Cash Flow

₹ Cr
524790 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4
7
10
5
9
10
14
14
18
16
−5
4
Investing
−3
−7
−8
−4
−5
−6
−12
−17
−16
−13
−5
−2
Financing
−2
0
−2
−1
−3
−3
−2
2
−3
−3
16
−8
Net Cash Flow
0
0
0
0
1
0
0
−1
0
0
6
−6
Free Cash Flow
1
0
2
1
2
3
7
−3
5
3
−11
2
CFO/OP
52
119
162
64
50
51
59
214
1,981
149
−76
21

Ratios

524790 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
100
117
105
124
95
97
102
125
152
185
202
216
Inventory Days
44
55
73
72
71
102
110
110
139
128
166
132
Days Payable
184
235
260
251
190
211
183
212
282
324
315
262
Cash Conversion Cycle
−40
−63
−83
−55
−24
−12
29
24
9
−11
53
86
Working Capital Days
−30
−38
−50
−34
−15
7
21
9
−12
−20
3
27
ROCE %
19%
11%
13%
13%
35%
35%
34%
6%
4%
6%
2%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Everest Organics insights

65 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 60.61%
  • Public 26.26%
  • Others 13.11%
  • DIIs 0.02%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Everest Organics

What does Everest Organics Ltd do?
Everest Organics Ltd (EOL) makes active pharmaceutical ingredients (APIs), the main medicinal ingredients in finished medicines, and chemical intermediates used to make APIs. Its factory is at Aroor, Sangareddy, Telangana.
Where is Everest Organics Ltd (EVERESTO) listed?
Everest Organics Ltd trades under code 524790 on the BSE.
Which sector does Everest Organics Ltd belong to?
Everest Organics Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Everest Organics Ltd?
Everest Organics Ltd trades at a PE ratio of 44.34 as of 4 Nov 2026, on earnings per share of ₹5.41, against a book value of ₹79.69 per share.
What is the 52-week high and low of Everest Organics Ltd?
Over the last 52 weeks Everest Organics Ltd has traded between ₹197 and ₹536.4 as of 4 Nov 2026.
Does Everest Organics Ltd pay dividends?
Everest Organics Ltd has a dividend yield of 0.21%.
What is the Return on Equity (ROE) of Everest Organics Ltd?
Everest Organics Ltd reported a return on equity of 7.63%. Its debt-to-equity ratio is 0.66.

Company Information

Everest Organics Ltd (EOL) makes active pharmaceutical ingredients (APIs), the main medicinal ingredients in finished medicines, and chemical intermediates used to make APIs. Its factory is at Aroor, Sangareddy, Telangana.

Website everestorganicsltd.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524790.md for Everest Organics Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month